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Key points 
 Induction of senescence, a stable state of cell cycle arrest, was originally described 
in normal cells, but it can also be induced in tumour cells in response to various 
stresses. 
 Senescent cells are metabolically active. In contrast to tumour cells, which 
typically preferentially use glycolysis in the presence of oxygen to generate 
energy, senescent cells can exhibit hyperactive mitochondrial respiration 
(oxidative phosphorylation ) in some contexts. 
 Autophagy is activated during senescence, but its importance varies depending on 
the context. 
 The senescence-associated secretory phenotype (SASP) mediates the diverse 
functionality of senescent cells in an autocrine and paracrine manner, including 
reinforcing or inducing senescence, activating an immune response, and even 
promoting tumorigenesis, depending on the context. 
 Senescent cells can be eliminated through a SASP-induced immune response, 
which can involve both innate and adaptive immunity.  
 Various triggers such as tissue damage or tumorigenesis-associated stresses can 
cause stromal cell senescence, which may either facilitate or inhibit tumour 
progression, depending on the context.  
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Abstract 
The core aspect of the senescent phenotype is a stable state of cell cycle arrest. 
However, this is a disguise that conceals a highly active metabolic cell state with 
diverse functionality. Both the cell autonomous and the non-cell autonomous 
activities of senescent cells create spatio-temporally dynamic and context-dependent 
tissue reactions. For example, the senescence-associated secretory phenotype (SASP) 
provokes not only tumour suppressive but also tumour promoting responses. 
Senescence is now increasingly considered as an integrated and widespread 
component that is potentially important for tumour development, suppression and the 
response to therapy.  
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Introduction 
Cellular senescence, a state of stable exit from the cell cycle, has often been compared 
with apoptosis as an intrinsic tumour suppressor mechanism. Various triggers induce 
either phenotype depending on the cell type and context. Since senescent cells are 
permanently arrested it was often assumed that senescence was functionally similar to 
apoptotic cell death, in terms of its effects on tumour suppression and tumour therapy. 
However, as described in this Review, the view that senescence is an end point of a 
stress response has been considerably revised over the past decade
1
. Senescence has a 
heterogeneous phenotype in terms of cellular markers: multiple markers are required 
to define senescence with confidence. Senescence typically depends on the p53 and 
RB pathways, but other effector programs confer additional layers of regulation. 
These include telomere shortening and a persistent DNA damage response, autophagy 
and other metabolic alterations, altered protein secretion, and epigenetic gene 
regulation
2-4
. These pathways collectively contribute to the establishment and 
maintenance of senescent cells and their fitness.  
The senescence-associated secretory phenotype (SASP) in particular provides 
senescent cells with diverse functionality, and the senescence response can have 
profound cell autonomous and non-cell autonomous activities in vivo
5,6
. Paradoxically, 
the diverse effects of the SASP include not only tumour suppressive but also 
tumorigenic aspects. However, there is another twist in the view of the long-term fate 
of senescent cells, which, similar to apoptotic cells, can be cleared from lesions in 
some contexts. We have summarised senescence markers and senescence associated 
effector programs in a recent review
4
. Here, we provide an overview of the different 
roles that senescence has in the development of cancer. We initially focus on the more 
established cell autonomous role of senescence as a tumour suppressive mechanism, 
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emphasising the emerging metabolic features of senescent cells. We then discuss the 
non-cell autonomous activities of senescence, including their functionality in both 
tumour suppressive and tumorigenic contexts and their potential impact on the 
outcome of cancer treatment. Although the focus of this review is on analysing 
senescence in cancer, its implications in other biological contexts are also briefly 
summarised in Box 1. 
 
Senescence in pre-neoplasia 
 
Cellular senescence was initially described in human diploid fibroblasts (HDFs), 
which, in contrast to immortalised cells, undergo a ‘permanent’ proliferative arrest 
after long-term cell culture in vitro
7,8
. This replicative senescence is mainly attributed 
to progressive telomere shortening, which provokes a persistent DNA damage 
response and the activation of tumour suppressive signals, including activation of the 
p53 and the p16RB pathways9-11. In contrast to humans, mice have long telomeres 
and adult mouse somatic cells often retain telomerase activity, thereby maintaining 
telomere length
12
. Loss of telomerase activity in mice has been shown to suppress 
tumorigenesis in various tumour models
13-16
 and telomere attrition-induced 
senescence is implicated in these tumour suppressive effects
17
. However, a modest 
increase in the incidence of spontaneous tumours in highly proliferative cells is 
evident in these mice, possibly owing to increased chromosomal instability
18
. 
The tumour suppressor function of senescence was further reinforced by the 
discovery of oncogene-induced senescence (OIS). OIS was initially described in 
culture, where the ectopic expression of oncogenic HRAS-G12V, or its downstream 
effectors paradoxically led to premature senescence
19-21
. However in 2005 a series of 
studies
22-26
 identified senescence in several premalignant tumours, both in humans 
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and mice. The loss of tumour suppressors, such as PTEN
23 
(BOX 2), RB
27
, 
neurofribromin 1 (NF1)
28
 and inositol polyphosphate-4-phosphatase, type II 
(INPP4B)
29
, has also been associated with senescence in premalignant tumours.  
 
Therapy-induced senescence 
Senescence can also be induced in response to therapy-induced genotoxic stress. 
Although therapy-induced senescence (TIS) was first described in tumour cell lines
30
 
not long after the discovery of OIS
19
, TIS is a relatively unexplored area. This is 
perhaps in part because tumour cells often exhibit a mixed phenotype of apoptosis and 
senescence when treated with chemotherapeutic agents, whereas HDFs are typically 
resistant to apoptosis and readily undergo senescence. Te Poele et al.
31
 showed that 
TIS was also evident in human breast cancer samples taken from patients who had 
undergone pre-operative neoadjuvant chemotherapy. These tumours tended to be 
positive for senescence-associated-ß-galactosidase (SA-ß-gal) activity and expression 
of p16, which are widely used markers of senescence, compared with non-treated 
tumours. Although this study suggested that a senescence-like phenotype can be 
induced in tumour cells in vivo, the clinical relevance of TIS remains unclear. 
The first genetic evidence that senescence induction might represent a 
worthwhile therapeutic goal was shown in an Eµ-Myc mouse B cell lymphoma model, 
where Myc is expressed under an immunoglobulin heavy chain enhancer-promoter 
and therefore restricted to the B-cell compartment. Schmitt et al.
32
 compared 
chemotherapeutic efficacy in Eµ-Myc lymphomas with Eµ-Myc; Trp53
-/-
 lymphomas, 
and Eµ-Myc lymphomas expressing the ectopic anti-apoptotic protein Bcl-2 (Eµ-Myc; 
Bcl2). Eµ-Myc; Trp53
-/-
 tumours showed a delayed regression followed by recurrence 
after cyclophosphamide (CTX) treatment. By contrast, Eµ-Myc; Bcl2 tumours, which 
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are resistant to apoptosis, showed no alteration in tumour size and hence appeared not 
to have responded to CTX. However, the prognosis of these mice was significantly 
better than the Eµ-Myc; Trp53
-/-
 mice because the cells in the Eµ-Myc; Bcl2 
lymphomas became senescent, although the Eµ-Myc; Bcl2 lymphomas also eventually 
progressed.  p53-dependent senescence could also be induced in Eµ-Nras
G12D
; Bcl2 
lymphomas treated with chemotherapy
22
 and in Myc-driven lymphomas in response to 
Myc inactivation
33
. It was also shown that reactivation of endogenous p53 induces 
senescence in various p53-defective tumours, including Myc-driven lymphomas, 
Hras
G12V
-driven liver cancer, and sarcomas
34-35,36
. Although p53 has important roles 
both in apoptosis and senescence, these studies suggest that the p53-mediated 
senescence pathway can affect therapeutic outcome, particularly in an apoptosis-
defective context. Some of the most relevant models of therapy-induced senescence in 
the in vivo setting are summarized in Table 1, and reviewed in 
37-39
. 
 
 
Senescence and intracellular pathways 
 
[Au; for clarity and flow, I think that Box 3 should be incorporated into the main text 
here (even though this will increase the length of the main text). Please ensure that the 
references are in the correct order when you make this change.]  
 
Mitochondrial metabolism 
Recent studies on senescence-associated metabolic features have provided insights 
into cancer biology and therapy. Specific metabolic programs in cells adapt to genetic 
changes or environmental cues. For example, tumour cells often exhibit a shift in 
glucose metabolism from mitochondrial oxidative phosphorylation to glycolysis even 
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in the presence of oxygen (the Warburg effect)
40
 (FIG 1). Emerging evidence 
indicates that senescent cells also shift glucose metabolism, but in a way that is 
distinct from proliferating cancer cells
41-43
.  
Kaplon et al.
41
 recently showed that increased mitochondrial oxidative 
phosphorylation is critical for OIS induction. Pyruvate is at the node between 
glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle. Pyruvate can be 
converted by the pyruvate dehydrogenase (PDH) complex to acetyl-CoA, which 
enters the TCA cycle (FIG. 1). Cells in culture expressing either oncogenic BRAF-
V600E or RAS-G12V that undergo OIS have increased PDH activity
41
. Down-
regulation of PDH activity abrogated BRAF-V600E-induced senescence, whereas 
activation of PDH was sufficient for senescence induction in normal cells, indicating 
a key role for PDH in OIS. A similar increase in mitochondrial metabolism, resulting 
in increased oxygen consumption, energy production, lipid catabolism and increased 
levels of reactive oxygen species (ROS), was found in TIS of Eµ-Myc;Bcl2 
lymphomas
43
.  
These studies highlight the stark contrast between senescent and proliferating 
tumour cells with respect to the pyruvate flux into the TCA cycle for efficient energy 
production (FIG. 1). Interestingly, activation of PDH in mutant BRAF-driven human 
melanoma cells not only blocks tumorigenesis but also sensitises them to the BRAF 
inhibitor PLX4720 (an analogue of vemurafenib), eliminating treatment-resistant cell 
populations
41
. This finding is encouraging, because although the ATP-competitive 
BRAF inhibitors, vemurafenib and dabrafenib have shown dramatic effects on BRAF-
V600E-driven melanomas in the clinic, this response is almost inevitably temporary
44
. 
Thus, developing combination therapies with BRAF inhibitors and drugs that activate 
PDH might be a promising strategy. PDH is negatively regulated through 
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phosphorylation by pyruvate dehydrogenase kinase (PDK). PDK1, one of four known 
PDK isozymes, is down-regulated in BRAF-V600E-induced senescence, and RNA 
interference (RNAi) against PDK1 induces sensitivity of the BRAF-V600E 
expressing cells to vemurafenib
41
. Dichloroacetate, a small molecule inhibitor of PDK, 
has been used in humans for the treatment of lactic acidosis and inherited 
mitochondrial diseases for decades and dichloroacetate has already been implicated in 
cancer therapy
45,46
. In theory, this drug could be used to inhibit PDK, and hence 
activate PDH, in melanoma, but would all melanomas respond to this therapy? 
Interestingly, recent studies have identified two distinct sub-groups in human 
melanoma: a conventional glycolytic group and a group characterised by high rates of 
oxidative phosphorylation
47,48
. In the latter group, microphthalmia-associated 
transcription factor (MITF), the oncogenic melanocyte lineage-specification 
transcription factor, drives peroxisome-proliferator-activated receptor γ coactivator 1α 
(PGC1 47,48 and around 10% of human melanomas had an 
above average expression level of PGC148. PGC1 is a transcriptional coactivator 
and promotes mitochondrial respiration and, at the same time, induces many ROS-
detoxifying enzymes
49
. Consistently, MITF and PGC1-expressing melanoma cells 
are more resistant to oxidative stress. Importantly, no correlation was observed 
between PGC1 expression and BRAF mutation status48. Thus it would be important 
to carefully validate the effect of PDK1 inhibition, with or without BRAF inhibitors, 
in the MITF and PGC1-expressing subset of melanomas, which appear to be 
associated with a poor prognosis
47,48
. 
Other metabolic pathways, such as the p53-mediated regulation of malic 
enzymes (MEs), have been implicated in the regulation of senescence. ME1 and ME2 
expression is repressed by p53 and the MEs negatively regulate p53, thus depletion of 
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the MEs results in p53 activation in a feed forward manner, thereby inducing 
senescence
50
 (FIG. 1). However, it is possible that ME depletion-associated metabolic 
alterations also regulate senescence. MEs catalyse the oxidation of malic acid into 
pyruvate, using NADP+ or NAD(P)+ as cofactors. MEs are a major source of 
NADPH for the antioxidant system and lipid biosynthesis, and have also been 
implicated in increased glutamine consumption in tumours
51
. Thus MEs can 
potentially divert the TCA cycle intermediate, malic acid, to the synthesis of 
macromolecules to form building blocks. Jiang et al.
50
 showed that depletion of MEs 
induces senescence with the reduction of the NADPH levels. Consistently, these cells 
also show ROS induction and reduced lipid synthesis. In addition, although 
mitochondrial respiration was not tested in this context, a reduction in ME activity 
may facilitate TCA cycle flux by reducing the malate shunt, thereby reinforcing 
senescence-associated PDH activation (FIG. 1). Interestingly, ME2 depletion also 
induces differentiation in K562 erythroleukemia cells
52
. Although the role of the MEs 
in the context of OIS and TIS is still unclear
50
, these studies all seem to point to a 
senescence-associated metabolic shift toward maximal energy production at the 
expense of macromolecule synthesis and reducing power.  
Consistent with this view, Quijano et al.
53
 showed that HRAS-G12V-induced 
senescent HDFs exhibit reduced lipid synthesis and increased fatty acid (FA) 
oxidation, leading to enhanced mitochondrial oxygen consumption. As Dörr et al.
43
 
suggest, such a diversion into energy production would also be beneficial for 
supporting energy consuming activities in senescent cells, such as producing high 
levels of secretory proteins (as evident in a SASP) and autophagy (see below). Indeed, 
Quijano et al.
53
 showed that the inhibition of FA oxidation in OIS cells results in a 
reduced production of many SASP components. Unlike rapidly proliferating tumour 
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cells, senescent cells would not need a continuous supply of macromolecules, such as 
lipids and nucleotides. Hence, it would be interesting to know whether the reduced 
capacity for building block production during senescence is a consequence or a cause 
of the phenotype. Finally, increased ROS levels due to hyperactive mitochondrial 
respiration as well as reduced levels of NADPH are also likely to contribute to 
senescence induction, further suggesting the robust involvement of a metabolic shift 
in senescence.  
In contrast to these recent studies, suggesting the highly active state of 
mitochondrial respiration during OIS and TIS, early studies had associated senescence 
with mitochondrial dysfunction
54
, particularly in the ageing and replicative 
senescence contexts
55,56
. While it was recently shown that the metabolic profiles of 
OIS and replicative senescence HDFs are highly distinct
53
, inefficient mitochondrial 
energy production was also observed in the OIS model
57
. The reason for the apparent 
discrepancy is not clear. However, the dysfunctional mitochondria in HDFs that have 
undergone OIS or replicative senescence were accompanied by active mitochondrial 
biogenesis
55,57
, with a concurrent up-regulation of PGC157, which is a major 
regulator of mitochondrial biogenesis, thus increasing respiration, antioxidant 
defences, and FA oxidation
49
. Interestingly, they also noted increased mitochondrial 
mass at the perinuclear region
57
, where macroautophagy (refereed to as autophagy 
hereafter), the machinery for the bulk degradation of macromolecules and organelles, 
is often activated upon stress
58-60
. These data suggest the potential of active 
mitochondrial turnover in OIS cells. Interestingly, it was shown that inefficient 
“mitophagy” is associated with mitochondrial dysfunction in some tumour cells61. As 
we discuss below, autophagy can be induced during OIS
59
, and it can cause different 
effects on the senescence phenotype during OIS, depending on the level of its 
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induction
62
. In addition, the intensity of the oncogenic stress also has a profound 
effect on the dynamics of the proliferative and senescence responses
63
. Shifting the 
fine balance between mitochondrial biogenesis and recycling might, at least in part, 
explain the phenotypic heterogeneity. 
 
Autophagy 
Autophagy is a genetically regulated catabolic process where cytoplasmic 
components, including organelles, proteins and other macromolecules, are encircled 
by autophagic vesicles and are delivered to lysosomes for bulk degradation. 
Autophagy occurs both basally and in response to metabolic or other stresses
64
. 
Autophagy has key roles in ageing and cancer, but its links to senescence are just 
emerging
65
.  
The role of autophagy in cancer is multifactorial and highly context 
dependent
66,67
. Autophagy is recognised as a survival factor for tumour cells under 
metabolic and therapeutic stresses
66,68
. However, genetic evidence also suggests 
tumour suppressive roles for autophagy
69-72
.  
Increased autophagic activity during senescence has been shown in different 
models
4,73
. SA-ß-gal is a lysosomal enzyme
74
 and is frequently expressed in senescent 
cells that have autophagic vesicles
58,75
, suggesting that autophagy might be an 
integrated part of the senescence program. Its functional role in senescence, however, 
appears to differ depending on the experimental system
65
. Autophagy is dynamically 
activated during OIS and facilitates the synthesis of interleukin 6 (IL-6) and IL-8, 
major components of the SASP
58,59
. A positive correlation between autophagy and 
senescence has also been observed in other models including OIS and TIS in culture, 
where the inhibition of autophagy often delays senescence induction
76-82
. Consistent 
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with its cytoprotective function, blocking autophagy during senescence induction can 
also result in cell death
83
 or even the exacerbation of senescence
62,84
. One speculative 
explanation for this apparent discrepancy would be that, in addition to the role of 
autophagy on senescence effectors (for example, the SASP), its cytoprotective effect 
could divert the stress response towards senescence rather than cell death. Thus the 
outcome of autophagy deficiency in pro-senescence conditions may be senescence 
bypass if cellular fitness had already been secured, or otherwise a severe reduction of 
cellular fitness: thus autophagy might affect the ‘quality’ of senescence.  
While data on the roles of autophagy in senescence in vivo are relatively 
limited,
43,59
 in their Eµ-Myc;Bcl2 model, Dörr et al. recently showed that activated 
autophagy has a pro-survival role, protecting against proteotoxic stress, which is 
associated with an increased production of SASP components during TIS
43
. Thus, in 
contrast to the OIS model in culture, autophagy inhibition results in the selective 
killing of tumours due to endoplasmic reticulum (ER) stress in this context. 
Although the majority of studies have indicated that autophagy inhibition is 
beneficial for cancer patients (reviewed in
85,86
), it is not always the case. Recently, 
Rosenfeldt et al.
87
 have investigated the role of autophagy at different stages of 
Kras
G12D
-driven pancreatic tumorigenesis. These mice develop pancreatic 
intraepithelial neoplasias (PanINs), which express markers of senescence
24
, however 
these lesions can eventually progress to pancreatic ductal adenocarcinoma (PDA). In 
this model, autophagy deficient mice exhibit a marked but transient accumulation of 
early PanIN accompanied by increased rates of apoptotic cell death, and these lesions 
never progress to late stage PanINs or PDA
87
. Thus, autophagy seems to have a 
cytoprotective role in this setting. However, the same study showed that when 
Kras
G12D
-driven PDA development is accompanied by loss of Trp53 (and is thus 
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senescence defective), autophagy deficiency instead accelerated tumour progression. 
Autophagy deficient cell lines derived from these tumours had higher levels of 
intracellular glucose, glycolytic intermediates and components of the pentose 
phosphate pathway whereas the TCA cycle was unaffected, suggesting that the 
autophagy defect in Trp53-null PDA provides metabolic advantages for proliferation, 
reminiscent of the Warburg effect.  
Interestingly, the effect of autophagy inhibition in Kras
G12V
-driven lung 
tumorigenesis (another OIS model
24
) is distinct from the pancreas model. In the lung 
model, regardless of p53 status, autophagy deficiency diverts adenoma or 
adenocarcinoma into oncocytoma, a rare and predominantly benign tumour 
characterised by the accumulation of respiration-defective mitochondria
88
. Thus, in 
contrast to the pancreas model, autophagy deficiency (by autophagy related 7 (Atg7) 
knockout) suppresses Kras
G12D
-driven lung cancer development even in the absence 
of Trp53; presumably this is partially due to mitochondrial dysfunction. This is 
consistent with the previous study from the same group that found that autophagy 
inhibition in nutrient starved conditions in cells that are ‘addicted’ to autophagy 
(particularly cells expressing oncogenic RAS) can result in cell death accompanied by 
the accumulation of dysfunctional mitochondria
61
.  
Although the precise role of autophagy in these OIS models is still unclear, 
these studies highlight the complex link between autophagy and mitochondrial 
respiration. Autophagy also appears to be required for the increase in oxygen 
consumption during RAS-induced senescence in MEFs, and TIS cells with 
hyperactive mitochondrial respiration die on autophagy inhibition
43
. Thus to reconcile 
the apparently distinct roles for autophagy in tumorigenesis between the different 
tissues, it is tempting to speculate that autophagy might somehow regulate the balance 
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between glycolysis and mitochondrial respiration, favouring the latter and, depending 
on the underlying metabolic stress, cells would develop either a glycolytic state or 
metabolic crisis
61
. It is also possible that the activated mitochondrial respiration 
reported in senescence models is, at least in part, dependent on intact autophagy. 
 
Senescence and the extracellular environment  
Senescence-associated secretory phenotype (SASP) 
The tumour suppressor function of senescence has been largely attributed to the lack 
of proliferative capacity of senescent cells. However, increasing evidence, particularly 
from sophisticated mouse models, indicates that senescent cells actively communicate 
with neighbouring cells and the extracellular matrix through a plethora of secretory 
factors, including extracellular proteases, cytokines and chemokines, and growth 
factors. Such studies have revealed the functionality as well as the dynamic longer-
term fate of senescent cells in vivo
89,90
. The SASP (also called the senescence-
messaging secretome, SMS) adds enormous complexity to the implications of 
senescence in cancer. The nature of the SASP and its targets, and the overall 
downstream outcomes, vary considerably depending on the cellular context, type of 
stress, and type of model used (FIG. 2).  
Various factors regulate SASP, both at the transcriptional and post-
transcriptional levels, contributing to the diverse outputs of senescence
58,59,91-96
. 
Importantly, SASP factors seem to form a hierarchical network, in which the signal is 
transduced and amplified. For example, senescence was recently shown to be closely 
associated with inflammasomes, which play a central role in inflammation
93,97
. This 
concept predicts the existence of master regulator(s) of the SASP. Currently, 
proinflammatory cytokines, including IL-1 and IL-6, and their regulators have been 
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proposed as major upstream regulators of SASP, and inhibition of either of them 
results in the collapse of the cytokine network in culture
91,93,98,99
.  
Some SASP components, for example matrix metalloproteinase 3 (MMP3) 
and plasminogen activator inhibitor 1 (PAI1), have long been used as markers of 
senescence
100,101
. Although PAI1 has since been shown to be a positive effector of 
senescence
102
, some soluble factors, such as MMP3, were known to promote 
tumorigenesis in neighbouring pre-malignant epithelial cells through paracrine 
effects
103,104
. Later studies reinforced the importance of the paracrine activities of the 
SASP as IL-6 and IL-8 secreted from senescent cells promote tumorigenesis in pre-
malignant, but not normal cells. However, these same factors can facilitate senescence 
in a cell-autonomous fashion, thus amplifying the phenotype
91,92,105
, and paracrine 
pro-senescence factors, such as insulin-like growth factor binding protein 7 (IGFBP7), 
IL-1 and transforming growth factor-β (TGFß), were also identified6,93,106,107, although 
the role of IGFBP7 as a paracrine senescence mediator in melanocytes is a matter of 
debate
108,109
. Thus it is conceivable that, in addition to its cell-autonomous role, 
senescence could also confer a tumour suppressive microenvironment during the early 
stages of tumorigenesis. However, this might be at the risk of a sudden change of 
senescence to a tumorigenic factor with the appearance of ‘senescence-escapers’ (or 
de novo pre-malignant cells). These concerns would also be relevant in attempting to 
use the induction of senescence as a cancer therapeutic goal, where the SASP might 
drive the proliferation of surviving tumour cells
110
.  
 
Clearance of senescent cells through an immune response 
Increasing evidence indicates that senescent cells can be eliminated through a SASP-
provoked immune response, which involves both innate and adaptive immunity
111,112
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(FIG. 2). The involvement of an immune response also extends the anti-tumour role 
of the SASP toward established transformed cells in some tumour models. 
The first evidence for the clearance of senescent cells through an immune 
response came from a mouse liver carcinoma model where endogenous p53 could be 
restored by turning off Trp53-targeted RNAi after tumours had been established
34
. 
Re-expression of endogenous p53 induced senescence and the elimination of the 
senescent tumour cells was mediated by innate immune cells, including macrophages, 
neutrophils and natural killer (NK) cells, albeit in mice lacking an adaptive immune 
system. More recently, using a similar system Iannello et al.
113
 focused on the role of 
NK cells and described how the NK cells mediate elimination of senescent tumour 
cells. They found that the recognition of retinoic acid early inducible 1 (RAE1), a 
ligand expressed by tumour cells, by NKG2D (also known as KLRK1), an activating 
receptor expressed in all NK cells, is critical for the elimination of senescent tumors. 
NKG2D has been implicated in the detection and elimination of transformed and 
virus-infected cells
114
. These ligands are induced in response to stress pathways that 
are associated with tumorigenesis, and indeed RAE1 [Au; any particular isoform?] in 
liver tumour cells was highly expressed before and after p53 restoration
113
. This raises 
an interesting possibility that senescence induction in just a subset of tumour cells 
would allow NK cells to kill not only senescent but also non-senescent tumour cells if 
NK cells could be recruited to the lesion (FIG. 2). The immunosuppressive nature of 
the tumour microenvironment is known to limit the capacity of immune cells to 
interact with and kill tumour cells
115
. Thus, it would be interesting to know whether, 
in addition to the increase in the level of chemoattractants, senescence induction in 
tumour cells also causes a reduction in immunosuppressive factors produced by 
tumour cells and stromal cells.  
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Although the innate immune response is sufficient for the clearance of p53 
reactivation-induced senescent cells from the liver, the adaptive immune system was 
also shown to have an important role during tumour senescence in some mouse 
models
116
. For example, the depletion of MYC  in a mouse subcutaneous 
transplantation model of T cell acute lymphoblastic lymphoma (T-ALL), which 
carries tetracycline regulated MYC transgene, results in sustained tumour regression 
associated with senescence and apoptosis, where an adaptive immune response 
(involving CD4
+
 T cells in particular) was required for senescence induction and 
sustained tumour regression, but not for apoptosis induction
116
. Although altered 
levels of several cytokines were evident on MYC-depletion, this study did not 
examine how the senescent cells were cleared.  
A recent study conducted by Kang et al.
112
 addressed this question in great 
detail in the mouse liver OIS model, where the clearance of senescent cells also 
requires CD4
+
 T helper (TH) cells. They showed that stably transduced oncogenic 
Nras
G12V
 drives the SASP in hepatocytes in mice and that these senescent cells are 
surrounded by various immune cells and are cleared predominantly by infiltrating 
monocytes and macrophages
112
. The elimination of senescent cells by innate immune 
cells requires the CD4
+
 TH1 cell response. Indeed, in livers bearing Nras
G12V
-induced 
senescent hepatocytes, CD4
+
 T cells that recognize the new epitope formed by the 
G12V mutation in Nras, were identified. Remarkably, Nras-G12V-specific CD4
+
 T 
cells were absent when Nras
G12V
 was transduced into the livers of senescence-
deficient mice; or a double mutant of Nras
G12V/D38A
 was used, which cannot induce 
senescence. Furthermore, similar to the T-ALL senescence model, CD4
+
 T cells are 
required for sustained tumour regression. Thus this tumour associated antigen (TAA)-
19 
driven ‘senescence surveillance’ is an essential part of the tumour suppressor function 
of senescence.  
Which aspect of senescence contributes to the immune clearance of 
premalignant cells in vivo? Although this is not clear, it is conceivable that a 
senescence specific cocktail of immunomodulatory factors might be a key 
determinant. SV40 T-antigen (Tag) driven spontaneous hepatomas evade TAA-driven 
immune surveillance because of T-cell tolerance
117
. Although Tag is highly 
immunogenic, it binds both p53 and RB, thus efficiently blocking the senescence 
response. Interestingly, mice with Tag-driven hepatoma have high levels of TGF-ß1, 
which effectively suppresses T cell function but low levels of circulating interferon γ 
(IFN-γ)117. Such a strong dominance of TGF-ß1 function over IFN-γ might contribute 
to the T-cell tolerance of Tag in these mice.  
How general is ‘senescence surveillance’? Interestingly, in oncogenic 
Kras
G12D
-driven PanIN Kras-G12D seems to be non-immunogenic
115
. The reason for 
the contrast between the liver and pancreas models is unclear. However, it is 
noteworthy that in contrast to Kras-G12D activation during embryogenesis in the 
PanIN model, Nras
G12V
 was introduced directly into adult somatic cells in the liver. 
Thus the Kras-G12D epitope might be seen as a self-antigen and be subject to 
peripheral immune tolerance in the PanIN model. Interestingly, it was shown that 
pancreatic acinar cells, in which Kras-G12V is activated during adulthood, exhibit a 
low frequency of PanIN development and resistance to transformation, at least in part 
due to OIS
118
. It is conceivable that tumour susceptibility is different depending on the 
stage(s) of differentiation at which the cells are exposed to oncogenic stress. However, 
an alternative, highly speculative, explanation may be that adult onset of Kras-G12V 
activation in the pancreas may provoke senescence immune surveillance. The same 
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study also showed that episodic pancreatitis induced by caerulein, a decapeptide 
analog of the gastrointestinal peptide hormone cholecystokinin, inhibited the OIS 
program, thus facilitating malignant transformation in this model
118
. Further detailed 
characterisation of the immune response induced by either OIS or tissue damage in 
these different models will be necessary. Of note, it seems that senescence arrest can 
be tumour suppressive without any obvious involvement from senescence 
surveillance: human melanocytic naevi (an OIS model), remain non-proliferative for 
decades without transformation into malignant melanoma
25
. These observations 
collectively underscore the diversity of the communication between senescent cells 
(or senescent cells-to-be) and immune effector cells in different scenarios.  
 
Senescence in the stroma 
The paracrine activity of senescent fibroblasts on epithelial cells was originally shown 
primarily in in vitro co-culture or xenograft models, where fibroblasts induced to 
senesce in culture promoted the proliferation and invasiveness of their neighbouring 
(pre)malignant epithelial cells
91,103-105,119
. However, Scott Lowe’s group pioneered a 
mouse model to show stromal senescence in the in vivo setting
120
 (FIG. 3). During 
liver injury, quiescent hepatic stellate cells (HSCs) are activated into proliferative and 
fibrogenic myofibroblasts, which contribute to liver fibrosis
121
. Using a well-
established mouse model of liver fibrosis induced by chronic treatment with the liver-
damaging agent carbon tetrachloride (CCl4), they showed that activated HSCs become 
senescent, exhibiting a typical SASP, including the expression of extracellular matrix 
degrading enzymes and proinflammatory cytokines. The SASP also attracts innate 
immune cells that in turn eliminate the senescent HSCs and facilitate the resolution of 
fibrosis
94,120
. Therefore, timely activation of HSCs and elimination of senescent 
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activated HSCs are critical for tissue integrity in this model. Although in this study it 
was not clear how activated HSCs become senescent, a separate study showed that the 
matricellular protein CCN1 (also known as CYR61), which is secreted from damaged 
hepatocytes, can trigger senescence in activated HSCs
122
 (FIG. 3). CCN1 can also 
promote myofibroblast senescence, which is associated with the expression of 
antifibrotic genes in the skin, thus CCN1 mediated stromal senescence might be 
involved in wound healing
123
.  
These data indicate that senescence in the context of some forms of tissue 
damage involves the spatio-temporal control of secreted protein levels as well as the 
content of SASP, which in turn modulates the senescence phenotype and dynamically 
regulates the surrounding tissue integrity; eventually contributing to the resolution of 
the lesion. Such a dynamic senescence process also seems to affect local 
tumorigenesis. In addition to fibrosis, senescent activated HSCs limit hepatocellular 
carcinoma (HCC) development in the presence of the chemical carcinogen diethyl 
nitrosamine (DEN), at least in part through activating a ‘classical’ tumour-suppressive 
M1 phenotype of macrophages, which provides an anti-tumour microenvironment and 
eventually eliminates senescent HSCs (FIG. 3). Interestingly, senescence in activated 
HSCs and the subsequent SASP-mediated activation of M1-macrophages are largely 
dependent on p53: Trp53-deficient HSCs continue to proliferate, stimulate the 
tumour-promoting M2 macrophages, and increase both cirrhosis and HCC 
development. Thus, p53 has a non-cell autonomous tumour suppressive role
94
. The 
non-cell autonomous tumour suppressive role for p53 was also proposed by an earlier 
study, where p53 was shown to buffer the expression of tumorigenic SASP 
components in senescent cells, thus restraining the tumorigenic microenvironment
105
. 
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These studies exemplify the anti-tumour effects of stromal cell senescence and 
the accompanying SASP. However, another recent study suggests that the SASP of 
senescent HSCs can also promote tumorigenesis. Dietary or genetic obesity in mice 
can affect gut microbiota, and increased concentrations of the gut bacterial metabolite 
deoxycholic acid (DCA), which occurs during obesity, induces a SASP in HSCs, via 
enterohepatic circulation. In the presence of the chemical carcinogen DMBA, DCA 
promotes HCC development in the obese mice
97
. Thus, in contrast to the CCl4-
induced liver damage model, DCA-induced senescent HSCs in the obesity model 
seem to be tumorigenic. The reason behind the apparently opposing effects of 
senescent HSCs on HCC development is not known. The long-term fate of senescent 
HSCs and the nature of the immune response triggered by the SASP were not 
examined in the obesity model. However, it was noted that, unlike the CCl4 treated 
mice, the obese mice did not develop fibrosis in the liver, suggesting that the nature of 
the tumour microenvironment may be substantially different between these two 
models. The authors fed DCA to non-obese mice and DMBA failed to increase HCC 
development. Thus some other obesity-related pro-tumorigenic factors may cooperate 
with senescent HSCs to facilitate the pro-tumorigenic microenvironment. To better 
understand the switch in the impact of SASP on tumorigenesis, it would be important 
to comprehensively compare the SASP components of senescent HSCs between the 
two models. 
Stromal senescence was demonstrated more robustly using p16-reporter 
mice
124
. With a number of different cancer models in the p16-reporter mouse, 
including transgenic autochthonous, transplanted and spontaneous tumours, the 
authors showed that early neoplastic events induce stromal senescence often much 
earlier than the tumours became palpable. Although further senescence validation 
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using additional markers is necessary, these remarkably similar findings across 
different tumour models suggest that stromal senescence activated by neoplastic 
events is generally tumorigenic. However, it is not entirely clear whether tumours 
develop due to, or despite of, the SASP of the stromal cells in these models.  
 
Cytokine-mediated senescence  
 
Recent studies have shown that some SASP components not only reinforce the 
senescence response in cells that are already primed for senescence, but also induce 
senescence in normal neighbouring cells in a paracrine fashion
93,106
. However, these 
senescence-inducing soluble factors have different sources. For example, the 
chemokine GRO1 (also known as CXCL1), which is secreted from transformed cells, 
can induce senescence in stromal fibroblasts
125
. In an Eµ-Myc lymphoma model, p53-
induced apoptosis of lymphoma cells led to the activation of macrophages to secrete 
TGFß1, which in turn induced senescence in lymphoma cells
36
. Thus tumour 
apoptosis can locally provoke cytokine-mediated senescence in this model. Note this 
study also reinforces the non-cell autonomous tumour suppressor role of p53, as 
mentioned above. Another example involves adaptive immunity and TH1 T cell 
cytokines that can directly drive cancer cells into senescence
126
. Using the classical 
SV40 Tag-induced carcinogenesis model of pancreatic cancer, where Tag is 
expressed in pancreatic islets under the control of the rat insulin promoter (RIP-Tag2 
mice
127
), Tag-activated CD4
+
 TH1 cells expressing a T cell receptor specific for the 
Tag peptide (Tag-TH1 cells) have a tumour suppressive role, which requires that the 
target tumour cells respond to both the IFNγ and tumour necrosis factor (TNF) signals 
produced by the Tag-TH1 cells
128
. Although Tag binds both RB and p53, it attenuates, 
rather than fully inactivates, their activity, thus their residual activities allow the RIP-
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Tag2 mice to exhibit progressive tumorigenesis with only a small portion of islets 
developing invasive pancreatic  cancer
127,129
. Treatment of mice with Tag-TH1 cells in 
this model induces a cell proliferation arrest in the tumors and improves the survival 
of these mice
128
. The TAA-expressing islets treated with Tag-TH1 cells are functional 
(i.e. they produce insulin), thus appeared to be in a state of tumour dormancy
128
. 
Although the relationship between tumour dormancy and senescence may be a matter 
of debate, the same group later showed that these cells were arrested due to 
senescence
126
. The senescence phenotype is dependent on the p16-RB pathway, thus 
unlike the aforementioned Tag-driven hepatoma model, the residual RB activity 
seems to be sufficient for senescence induction in this model
129
. Importantly, if the 
tumour cells fail to respond to either IFN or TNF, Tag-TH1 cells do not just fail to 
suppress tumour growth, instead they promote tumour growth in RIP-Tag2 mice
128
. 
A link between tumour dormancy and the immune response has been observed 
in different experimental tumour models
130
. For example, studies in a spontaneous 
mouse melanoma model suggest that dormancy in micrometastatic lesions is mediated 
by immunosurveillance
131,132
. In this model, tumour cells disseminate early during 
tumorigenesis, and these cells remain dormant for prolonged periods of time. 
Interestingly, cytostatic CD8
+
 T cells suppress the expansion of the disseminated 
tumour cells
132
. Precisely how CD8
+ 
T cells induce tumour dormancy is not shown in 
this model, however, CD8
+
 T cells also secrete cytostatic cytokines, including IFNγ 
and TNF. Thus, the combination of IFNγ and TNF induced-senescence in particular, 
might widely contribute to tumour control. Consistently, Braumüller et al.
126
 
confirmed that IFNγ and TNF induce senescence in a number of different cancers 
both in vitro and in vivo. 
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Chronic inflammation is generally a risk factor for tumorigenesis
133
, however, 
psoriasis, an immune-mediated cutaneous chronic inflammatory disease is associated 
with a reduced risk for cancer
134
. It is suspected that this might be because of 
senescence
135
. The development of psoriatic plaques is accompanied by activation of 
CD4
+
 T cells and other immune cells, which provide a plethora of cytokines and 
chemokines, including TNF and IFNγ136. Here also a TNF and IFNγ cocktail might 
provide a dominant tumour suppressor activity through cytokine-induced senescence.  
 
Concluding remarks  
Recent advances in our understanding of senescence biology have substantially 
extended the known pathophysiological roles of senescence. These studies suggest 
that senescence is a more widespread phenomenon than was previously thought (BOX 
1). The functional association of senescence with other regulatory phenotypes, such as 
mitochondrial metabolism and the immune response, requires further study. For 
example, metabolic intermediates of the TCA cycle affect epigenetic-mediated control 
of gene expression through regulating the modification of histones and DNA
137,138
. 
These pathways might well be altered in senescent tumour cells and stromal cells. 
Although in this review we have treated carbohydrate metabolism as a cell-
autonomous effector, it is conceivable that metabolic intermediates from different 
tissue compartments can transduce signals and nutrients to each other. Indeed, it has 
been proposed that the lactate extruded from glycolytic tumour cells may be taken up 
by tumour cells (and potentially senescent cells) undergoing oxidative 
phosphorylation to fuel the TCA cycle
139
.  
Senescent cells are by definition irreversibly arrested, however, in the 
senescence immunosurveillance model, senescence per se may not be a very efficient 
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tumour suppressor, at least in some tumour models. The analogy between senescence 
and dormancy in some tumours also implies that the in vivo senescence-like arrest 
may be unstable, because dormant tumour cells can regrow after long periods of 
time
130,140
. It is possible that a rare stochastic event of senescence escape occurs, in 
some cases facilitated by SASP, during the course of tumorigenesis. Much like 
dormant cells, senescent cells are resistant to apoptosis or mitotic catastrophe upon 
chemotherapy, thus if senescent tumour cells are not eliminated, the sustained 
expression of pro-tumorigenic cytokines can lead to a worse outcome
110
. It is also 
possible that the heterogeneity and complexity of the senescence phenotype may 
confer a spectrum of senescence intensity or quality
4
, thus in some contexts or tissues, 
coupling a stable cell cycle arrest with the eventual clearance of the senescent cells is 
necessary to limit tumorigenesis.  
Such a diverse senescence response is also relevant when considering 
senescence as a therapeutic option. For example, the outcome of endogenous p53 
reactivation can be senescence and/or cell death depending on the tumour type
35,141,142
. 
Even in the same tissue, the same triggers can either suppress (by inducing 
senescence) or promote tumorigenesis, as in the case for cytokine-induced 
senescence
128,143
. The partial induction of senescence in tumours could eradicate or 
exacerbate the tumours
110,113
. Either in an immune-mediated or non-immune manner, 
mechanisms for the selective elimination of senescent cells need to be explored 
further. Researchers have just started to accumulate examples of the high-order 
communication of senescence with the microenvironment in several in vivo models, 
but our current knowledge suggests that carefully individualised medical indications 
need to be considered when targeting senescence effectors for cancer therapy. A more 
detailed understanding of the integrity of the SASP in terms of both the expression of 
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the components and also its functional networks would help us to exploit senescence 
for optimal tumour suppression. 
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Box 1: Consequences of cellular senescence: aging and development  
Besides its role in tumour suppression and tumorigenesis cellular senescence has been 
linked to other processes, including aging and, most recently, mammalian embryonic 
development.  
 
Aging: The functional role of cellular senescence in organismal ageing is not entirely 
clear. On the one hand, accumulation of several senescence markers in aged 
individuals has been reported in various tissues
56
. On the other hand, the inverse 
correlation between the replicative lifespan of cells (such as skin fibroblasts) in 
culture and donor age appears to be controversial
144
. Thus ageing affects senescence, 
but how about the other way around? The compelling evidence for the functional 
relevance of senescence in ageing was shown in mice where age-dependent 
accumulation of p16-positive cells in tissue stem cell or progenitor cell compartments 
contributes to tissue degeneration, and p16 depletion attenuates some age-dependent 
phenotypes
145-147
. Interestingly, selective killing of those p16-expressing cells in a 
premature ageing mouse model also delays ageing phenotypes
148
. Importantly, unlike 
p16-ablation, elimination of p16-expressing cells does not facilitate tumorigenesis in 
this model. It is possible that the efficient turnover of stem or progenitor cells 
facilitates tissue regenerative capacity. It is also possible that ablation of the senescent 
cells attenuates the local and perhaps systemic effects of the secretory associated 
senescent phenotype (SASP), which might contribute to various aspects of ageing. 
 
Embryogenesis: Recently, two studies have uncovered a physiological function for 
senescence during mammalian embryonic development. Embryonic cell senescence is 
p21, but not p53, dependent, is accompanied by the SASP, and these cells are 
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eliminated by macrophages
149,150
. Thus, similar to apoptosis, senescence also 
contributes to embryonic patterning. Another study identified senescence in normal 
placenta, where cell fusion, mediated by the highly fusogenic glycoprotein 
endogenous retrovirus group W member 1 (ERVWE1), provides the maternal-fetal 
interface
151
. They showed that ERVWE1-mediated cell fusion induces senescence. 
Thus, senescence, which was long thought to be purely a stress response, also appears 
to be physiologically programmed. 
 
Box 2: PTEN loss-induced cellular senescence (PICS) 
Among senescence induced by loss of tumour suppressors, PTEN loss-induced 
cellular senescence (PICS) in prostatic intraepithelial neoplasia (PIN) has been 
extensively studied by Pandolfi’s group38,152. Pten heterozygosity promotes tumour 
initiation and proliferation in the prostate, but paradoxically, the complete loss of Pten 
can oppose prostate tumorigenesis by triggering a powerful p53-dependent cellular 
senescence response
38
. Consistently, the majority of prostate cancer patients at 
presentation have lost one allele of PTEN while maintaining intact TP53; whereas 
TP53 mutations and the complete loss of PTEN are both associated with advanced 
stage prostate cancer
153,154
. Alimonti et al. demonstrated a proof of principle that 
pharmacological inhibition of PTEN in prostate cancer that is wild type for TP53, 
results in the inhibition of tumorigenesis with senescence induction in a human 
xenograft model
152
. Since PTEN is a negative regulator of the PI3K-mTOR pathway, 
which is also often considered to be a target for cancer therapy, targeting PTEN may 
sound counter-intuitive. Interestingly, TP53 up-regulation upon PTEN inhibition 
appears to be dependent on mTOR activity, which increases TP53 translation
152
. Thus 
in some specific cases, such as tumours in which one allele of PTEN has become 
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inactive, PTEN inhibitors might be an option for cancer therapy. Of note, unlike OIS, 
PICS occurs in the absence of transient hyper-proliferation and a DNA damage 
response (DDR)
152
. As we discuss in the main text, pro-senescence treatment may 
provoke a tumorigenic microenvironment through the SASP in some contexts. The 
SASP, however, has been shown to be mainly regulated through persistent DDR
96
. 
Thus PICS might provide a unique opportunity, where pro-senescence therapy may be 
separable from the potential side effects derived from the SASP. It would be 
interesting to know whether PICS, which has been shown not to be associated with 
DDR, is accompanied by some type of SASP and, if so, how it affects the tumour 
microenvironment. 
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Figure 1. Glucose metabolism in OIS, TIS and cancer.  
Active mitochondrial metabolism has been shown in oncogene-induced senescence 
(OIS)
41,53
 and therapy-induced senescence (TIS)
43
. In the latter, active glucose uptake 
is maintained. The activity of pyruvate dehydrogenase (PDH) is positively and 
negatively regulated by pyruvate dehydrogenase phosphatases (PDP) and pyruvate 
dehydrogenase kinases (PDK), respectively. PDH is activated in senescent cells, 
induced by oncogenic BRAF or RAS, and PDH activation is accompanied by the 
induction of PDP2 and the suppression of PDK1 in BRAF-driven, but not in RAS-
driven, senescence
41
. Down-regulation of malic enzymes (MEs) in both fibroblasts 
and some tumour cell lines induces senescence
50
. In mammals there are three ME 
isoforms: the cytosolic, NADP+-dependent, ME1 (not shown in the figure); 
mitochondrial, NAD+ and NADP+ dependent, ME2; and mitochondrial, NADP+-
dependent, ME3. Although ME2 has been suggested to favour NAD+ over NADP+ as 
a cofactor, thus generating primarily NADH, it was shown that depletion of ME2 in 
cells in culture induces senescence with the reduction of the NADPH, but not NADH, 
levels
50
. The relevance of the levels of MEs in OIS models is not clear. Note this 
figure represents a collective view derived from recent studies using different models, 
thus should not be generalised. Ac-CoA, acetyl-CoA; FA, fatty acid; PPP, pentose 
phosphate pathway; TCA, tricarboxylic acid cycle. 
 
Figure 2. The senescence associated secretory phenotype (SASP) and its 
implication for the tumour microenvironment. 
a. General view: senescent cells actively communicate with their microenvironment 
through a plethora of secretory factors as part of the SASP. These factors can 
reinforce the establishment of senescence in their cell of origin in an autocrine manner. 
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They can also trigger the establishment of senescence in neighbouring cells in a 
paracrine manner. These signals lead to further secretion and hence to an 
amplification of the SASP. Senescence in this manner also modulates the extracellular 
matrix, enhances the transformation of predisposed cells and reinforces tumour 
growth. In addition, the SASP activates the immune system to eliminate senescent 
cells, which may remove potentially tumorigenic factors from the microenvironment. 
b. Senescence induction in tumours; three scenarios have been suggested. Immune 
cells, such as neutrophils, macrophages and natural killer (NK) cells recruited to the 
tumour lesion by the SASP eliminate the senescent cells
34
 and possibly non-senescent 
tumour cells
113
. However, sustained senescent cells can also facilitate tumour 
development
110
. 
c. In the case of Nras-G12V expressing hepatocytes their oncogene-induced 
senescence SASP leads to their clearance, predominantly by the infiltrating 
monocytes and the resulting macrophages
112
. The elimination of these senescent cells 
by the innate immune cells requires the CD4
+
 TH1 cell response. The CD4
+
 T cell 
activation depends on the presence of professional antigen presenting cells (APCs). 
Whether or not this occurs in other tissues, such as the pancreas, remains to be 
elucidated. 
 
Figure 3. Senescence in the stroma of the liver 
During liver injury quiescent hepatic stellate cells (HSCs) become activated. The 
HSCs become proliferative and fibrogenic myofibroblasts, which contribute to liver 
fibrosis by producing the extracellular matrix (ECM). Chronic liver damage (for 
example with exposure to CCl4) causes the activated HSCs to become senescent in a 
p53-dependent manner, exhibiting the typical SASP, including ECM degrading 
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enzymes and proinflammatory cytokines. The senescent activated HSCs thus limit 
excessive fibrosis (cirrhosis) and activate senescence surveillance through, for 
example, natural killer (NK) cells and anti-tumour M1 macrophages, and thereby 
limit the development of hepatocellular carcinoma (HCC)
94,120
 (a). By contrast, in an 
obesity model, increased levels of the gut bacterial metabolite deoxycholic acid 
(DCA) provoked HSC senescence and the SASP promoted HCC development
97
 (b). 
The matricellular protein CCN1, which is secreted from damaged hepatocytes, can 
also trigger senescence in activated HSCs, thereby limiting fibrosis
122
. 
Glossary 
Enterohepatic circulation 
The circulation between liver and intestine. Bile acids and other substances excreted 
from the liver are reabsorbed by the enterocytes into the hepatic portal vein.  
 
Inflammasome 
Cytosolic multiprotein innate immune complexes that assemble in response to a 
variety of stimuli, activating the pro-inflammatory serine protease caspase 1. 
Inflammasomes initiate innate immune responses by cleaving the inflammatory 
cytokines, pro-IL-1ß and pro-IL18, leading to their activation and secretion. 
 
Pancreatic intraepithelial neoplasias (PanIN) 
Induced by an activating mutation in KRAS and represent the most common 
precursor lesion of pancreatic ductal adenocarcinoma (PDA). 
 
NK cells 
34 
A subgroup of white blood cells, implicated in the killing of tumour or virus infected 
cells. They are generally considered as the cytotoxic lymphocytes of innate immunity 
due to their lack of antigen-specific cell surface receptors, but they can also exert 
antibody-dependent cell cytotoxicity. 
 
T helper 1 (TH1) cells 
A subset of CD4
+
 T helper cells that secrete cytokines, including IFNγ and TNF. They 
are canonically associated with the stimulation of CD8
+
 cytotoxic T lymphocytes and 
of macrophages as well as anti-tumour immunity. 
 
macrophages 
Generally speaking, M1 polarised macrophages inhibit cell proliferation and cause 
tissue damage whereas M2 polarised macrophages promot cell proliferation and tissue 
repair. The M1 and M2 macrophages promote the TH1 and TH2 responses, 
respectively. 
 
Cytokines  
A broad class of small proteins that comprise chemokines, interferons, interleukins, 
lymphokines and tumour necrosis factors that are produced by a variety of cells. 
 
Warburg effect 
A shift in glucose metabolism from mitochondrial oxidative phosphorylation to 
glycolysis in the presence of ample oxygen.  
  
NADPH 
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The reduced form of NADP+ and a source of reducing equivalents. Major sources of 
NADPH include the pentose phosphate pathway, NADP-dependent malic enzymes 
and NADP-dependent isocitrate dehydrogenase.  
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Table 1: Therapy-Induced Senescence Strategies in vivo 
 
LSL: LoxP-STOP-LoxP. 
Trp53ER: knockin allele, composed of endogenous Trp53 fused with the sequence encoding a modified ligand-binding domain of the mouse 
Approach Genetic background Senescence inducer Tumour phenotype References 
Molecular induction of senescence 
Trp53 activity restoration 
 
 
LSL-Trp53; Rosa26-Cre-ERT2 Endogenous p53 re-expression Regression of sarcomas 35 
Liver progenitor expressing 
ectopic Hras
G12V
 and Trp53 
RNAi Endogenous p53 re-expression Regression of liver tumours 34 
Eμ-Myc; Trp53ER; ectopic Bcl2  p53 reactivation  Senescence induction in lymphoma 36 
Telomerase dysfunction Eμ-Myc; ectopic Bcl2 mTR ablation  Suppression of Burkitt's lymphoma  17 
Oncogene inactivation 
 
Inducible MYC allele  MYC suppression 
Suppression of lymphoma, osteosarcoma, and 
hepatocellular carcinoma 33 
LSL-Kras
G12D
;
 
Ad-Cre lung 
infection Omo-myc expression Regression of lung tumours 155 
Inducible MYC allele in 
haematopoietic system MYC suppression 
Regression of T cell acute lymphoblastic 
lymphoma 116 
Inducible BCR-ABL allele in 
hematopoietic system BCR-ABL suppression Regression of pro-B cell leukemia 116 
Cell cycle deregulation 
 
Pten
+/-
 Skp2 ablation 
Lymphadenopathy and adrenal tumour 
abrogation 156 
Pten
loxP/loxP
; Pb-Cre Skp2 ablation Prostate cancer restriction 156 
Eμ-Myc  Cdk2 ablation Lymphomagenesis delay 157 
LSL-Kras
G12V
; RERTn
+/ERT
 Cdk4 ablation 
Suppression of non-small cell lung carcinoma 
development 158 
Pharmacological-induction of senescence 
DNA damage Eμ-Myc; ectopic Bcl2  cyclophosphamide Lymphoma regression 32, 43 
DNA damage Eμ-NrasG12V; ectopic Bcl2 Doxorubicin Lymphoma regression 22 
PTEN inhibitor Human prostate cancer xenograft  VO-OHpic [ Tumour growth inhibition 152 
MDM2 inhibitor Pten
loxP/loxP
; Pb-Cre Nutlin-3 Prostate tumour size decreased 152 
CDK4 inhibitor LSL-Kras
G12V
; RERTn
+/ERT
 PD0332991 
Suppression of non-small cell lung carcinoma 
development 158 
SKP2 inhibitor 
Human lung and prostate cancer 
xenografts SKP2 Inhibitor#25 Tumour growth inhibition 159 
mTOR inhibitor Eμ-Myc  Everolimus Lymphoma regression 160  
Immunotherapeutic-induction of senescence  
 
TH1 cell cytokines RIP-Tag2 IFNγ and TNF Pancreatic β-cell tumour regression 126 
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estrogen receptor (ER). 
VO-OHpic: Hydroxy(oxo)vanadium 3-hydroxypyridine-2-carboxylic acid trihydrate. 
mTR: mouse telomerase RNA component (also known as Terc). 
